Alex S. Bennett, PhD
NYU School of Global Public Health - Research Faculty
PhD, Applied History and Public Policy, Carnegie Mellon University
MPA, Public Policy Research and Analysis, University of Pittsburgh
BA/MA, History, University of Florida
Research Interests
Overdose prevention, Naloxone, Veterans health, Mixed-methods research, Opioids, Drug use, HIV/HCV prevention
Alex Bennett specializes in ethnographic, historical and mixed-methods public health and public policy research. His current project is a 4-year study of Opioid Use/Misuse and Overdose Risk among Veterans (R01DA036754) that will help determine ecological, structural, and psychosocial aspects of opioid use and overdose risk.  He has also received a supplemental grant  to train veterans in overdose prevention and response and naloxone administration and is tracking naloxone impacts on overdose survivors and responders. Dr. Bennett started work on overdose/HIV/HCV and drug abuse prevention and outreach services in the late 1990s with Prevention Point Pittsburgh, a community based harm reduction program and currently serves on the Board of Directors of the New York Harm Reduction Educators. Dr. Bennett has worked on substance use and overdose prevention and response both in academic and community-based settings conducting research, needs assessment, program development, service delivery, and evaluation work.
Principal Investigator, Overdose Risk Management and Compensation in the Era of Naloxone. Active
Principal Investigator, Opioid Misuse and Overdose Risk Patterns Among Recent Veterans. Completed
Principal Investigator, Technology to Increase Naloxone Uptake Among Opioid Users Who Initially Decline. Completed


Bennett AS, Elliott L (2021).
Naloxone’s role in the national opioid crisis – past struggles, current efforts, and future opportunities
Translational Research, 234, 43-57. doi: 10.1016/j.trsl.2021.03.001.

Elliott L, Crasta D, Khan M, Roth A, Green T, Kolodny A, Bennett AS (2021).
Validation of the Opioid Overdose Risk Behavior Scale, version 2 (ORBS-2)
Drug and Alcohol Dependence, 223, 108721. doi: 10.1016/j.drugalcdep.2021.108721. PMCID: PMC8113089.

Bennett AS, Freeman R, Des Jarlais DC, Aronson ID (2020).
Reasons people who use opioids do not accept or carry no-cost naloxone: Qualitative interview study
JMIR Formative Research, 4 (12), e22411. doi: 10.2196/22411. PMCID: PMC7787889.

Aronson ID, Bennett AS, Freeman R (2020).
Toward a human-centered use of technology: A stakeholder analysis of harm reduction and CBO staff
Harm Reduction Journal, 17 (1), 77. doi: 10.1186/s12954-020-00422-y. PMCID: PMC7570409.

Aronson ID, Freeman R, Taylor T, Bennett AS (2020).
Developing digital media to destigmatize emergency department Human Immunodeficiency Virus testing among sexual and racial minority youth: A hyper-iterative methodology
Cureus, 12 (3), e7209. doi: 10.7759/cureus.7209 . PMCID: PMC7138468.


Bennett AS, Bell A, Tomedi L, Hulsey EG, Kral AH (2011).
Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania
Journal of Urban Health, 88 (6), 1020-1030. doi: 10.1007/s11524-011-9600-7. PMCID: PMC3232410.

Dr. Bennett's Research Gate Profile